This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Plenty of Risks Remain In St. Jude's Stock

What's more, the operational performances, which once demonstrated enormous potential, continue to decelerate. In the recent quarter, not only did the company post another decline in overall revenue, led by a 6% decline company's pacemaker business, but one of St. Jude's largest segment, the cardiac rhythm management (CRM) business, dropped again by 2%. This comes after CRM declined by 7% in the April quarter.

If there was any good news, it was in the company's atrial fibrillation business, which grew better-than-expected at 12% year over year. But even in areas like this where St. Jude does well, it still wasn't enough to impress me -- not when Johnson & Johnson posted 16% growth.
[Read: <a target="blank" data-add-tracking="true" href=""><em>The Cost of Adulthood is $194,082</em></a>]

I don't want to make this sound like I'm just beating up on St. Jude. Though I've detailed some concerns with the company's products and its overall business, it's also worth noting that the company has done pretty much everything in its power, including subjecting the leads through rigorous testing to ensure the safety of customers. In fact, the FDA recently approved two St. Jude products that are said to help diminish the adverse effects of the malfunctioning leads.

So, there is progress being made as St. Jude has cooperated with the FDA's requirements. Nevertheless, to the extent that it justifies willfully dismissing the obvious risks that remain with this company, it doesn't seem prudent. At a P/E of 25, I rather take my chances with Johnson & Johnson -- as expensive as it might also be.

At the time of publication, the author held no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.
Richard Saintvilus is a co-founder of where he serves as CEO and editor-in-chief. After 20 years in the IT industry, including 5 years as a high school computer teacher, Saintvilus decided his second act would be as a stock analyst - bringing logic from an investor's point of view. His goal is to remove the complicated aspect of investing and present it to readers in a way that makes sense.

His background in engineering has provided him with strong analytical skills. That, along with 15 years of trading and investing, has given him the tools needed to assess equities and appraise value. Richard is a Warren Buffett disciple who bases investment decisions on the quality of a company's management, growth aspects, return on equity, and price-to-earnings ratio.

His work has been featured on CNBC, Yahoo! Finance, MSN Money, Forbes, Motley Fool and numerous other outlets.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
STJ $75.10 -0.54%
AAPL $92.69 -0.59%
FB $119.49 1.40%
GOOG $711.11 1.40%
TSLA $214.84 1.60%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs